Form 8-K · Current report
Prologis 8-K, filed Aug 6, 2026
- Filed
- CIK
- 0001045609
- Accession no.
- 0001104659-26-092072
Summary
Prologis received notice that underwriters J.P. Morgan Securities LLC and BofA Securities, Inc. exercised their option to purchase an additional 2,250,000 shares of Prologis common stock, following the company's offering of 15,000,000 shares that closed on August 5, 2026. The sale of the additional shares is expected to yield roughly $312.2 million in net proceeds after the underwriting discount and before estimated transaction expenses, with the closing set for August 7, 2026, subject to customary conditions.
Key points
- Prologis's recent underwritten offering of 15,000,000 common shares closed on August 5, 2026.
- The underwriters' over-allotment option covers 2,250,000 additional shares.
- Net proceeds of about $312.2 million are expected after the underwriting discount but before estimated transaction expenses.
- The additional shares are to be issued and sold on August 7, 2026, subject to customary closing conditions, under an effective shelf registration statement.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 8.01Other Events
From the filing
Item 8.01. Other Events. On August 5, 2026, Prologis, Inc. (the “Company” or “Prologis”) received notice that J.P. Morgan Securities LLC and BofA Securities, Inc., the underwriters in the Company’s recent underwritten offering of 15,000,000 shares of its common stock, $0.01 par value per share, which closed on August 5, 2026, exercised their right to purchase an additional 2,250,000 shares of common stock pursuant to the option granted to them by the Company in the underwriting agreement relating to the offering. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.